Developing Existing Healthcare Technologies to Deliver More Affordable and Effective Cancer Care

开发现有的医疗保健技术以提供更实惠、更有效的癌症护理

基本信息

  • 批准号:
    MC_UU_00004/02
  • 负责人:
  • 金额:
    $ 566.51万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Intramural
  • 财政年份:
    2021
  • 资助国家:
    英国
  • 起止时间:
    2021 至 无数据
  • 项目状态:
    未结题

项目摘要

Our aim is to reduce cancer deaths and the side effects associated with cancer treatments. We design clinical trials and other research studies that test several new approaches at the same time. This speeds up the evaluation of new therapies. Cancer is becoming more common, especially in low and middle income countries (LMICs) where it is estimated that 70% of cancers and 80% of cancer deaths will occur in 2020. We focus on the need for more affordable and effective cancer treatments. This is also important for high income countries. We test drugs that are already used for another disease. This is called repurposing. We also test whether radiotherapy, surgery and existing scanning techniques can be used in different and more efficient ways to improve the diagnosis and treatment of cancer. We will also test whether newer drugs (immuno–oncology) can be given for shorter periods of time with the same benefits and less side effects.In the future we will work on: a) cancers that are common and cause many deaths in LMICs; b) cancers that are less common which makes it difficult to run clinical trials; and c) studies to prevent cancer. Running a clinical trial in these areas can be challenging and not many research groups work in these areas. The impact of our work is recognised if the treatments we assess are recommended for patients by doctors because of our trials. Further impacts are to help increase research visibility and capacity in LMICs, including for example heling to develop Principal Investigators in countries. We also collect biological samples from trial participants and scientists evaluate them to increase our understanding of cancer.
我们的目标是减少癌症死亡和与癌症治疗相关的副作用。我们设计临床试验和其他研究,同时测试几种新方法。这加快了对新疗法的评估。癌症变得越来越普遍,特别是在低收入和中等收入国家(LMIC),据估计,到2020年,70%的癌症和80%的癌症死亡将发生。我们专注于需要更实惠和有效的癌症治疗。这对高收入国家也很重要。我们测试已经用于另一种疾病的药物。这叫做再利用。我们还测试了放射治疗、手术和现有的扫描技术是否可以以不同的、更有效的方式用于改善癌症的诊断和治疗。我们还将测试新药物(免疫肿瘤学)是否可以在更短的时间内提供相同的益处和更少的副作用。未来我们将致力于:a)在LMIC中常见并导致许多死亡的癌症; B)不太常见的癌症,这使得难以进行临床试验;以及c)预防癌症的研究。在这些领域进行临床试验可能具有挑战性,并且没有多少研究小组在这些领域工作。 如果我们评估的治疗方法因我们的试验而被医生推荐给患者,我们工作的影响就会得到认可。进一步的影响是帮助提高中低收入国家的研究知名度和能力,包括帮助各国培养首席研究员。我们还从试验参与者那里收集生物样本,科学家对它们进行评估,以增加我们对癌症的了解。

项目成果

期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Molecular selection of therapy in metastatic colorectal cancer: the FOCUS4 molecularly stratified RCT
  • DOI:
    10.3310/htnb6908
  • 发表时间:
    2022-12
  • 期刊:
  • 影响因子:
    0
  • 作者:
    L. Brown;D. Fisher;R. Adams;J. Seligmann;M. Seymour;R. Kaplan;S. Richman;P. Quirke;R. Butler;H. Roberts;J. Graham;R. Wilson;T. Maughan
  • 通讯作者:
    L. Brown;D. Fisher;R. Adams;J. Seligmann;M. Seymour;R. Kaplan;S. Richman;P. Quirke;R. Butler;H. Roberts;J. Graham;R. Wilson;T. Maughan
RADICALS trial statistical analysis plan
RADICALS 试验统计分析计划
  • DOI:
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Cook A
  • 通讯作者:
    Cook A
Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial.
Cardiovascular health: an important component of cancer survivorship
  • DOI:
    10.1136/bmjonc-2023-000090
  • 发表时间:
    2023-10
  • 期刊:
  • 影响因子:
    0
  • 作者:
    S. Cleary;Stuart Rosen;D.C. Gilbert;R. E. Langley
  • 通讯作者:
    S. Cleary;Stuart Rosen;D.C. Gilbert;R. E. Langley
Additional consensus recommendations for conducting complex innovative trials of oncology agents: a post-pandemic perspective.
  • DOI:
    10.1038/s41416-022-02051-7
  • 发表时间:
    2023-03
  • 期刊:
  • 影响因子:
    8.8
  • 作者:
    Blagden, Sarah P.;Yu, Ly-Mee;Ellis, Stephanie;Hughes, Helen;Shaaban, Abeer;Fennelly-Barnwell, Jonathan;Lythgoe, Mark P.;Cooper, Alison M.;Maignen, Francois M.;Buckland, Sean W.;Kearns, Pamela R.;Brown, Louise C.
  • 通讯作者:
    Brown, Louise C.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Mahesh Parmar其他文献

#30. Fractures in metastatic hormone-sensitive prostate cancer (mHSPC). Results from two phase 3 trials from the STAMPEDE platform
  • DOI:
    10.1016/j.jbo.2024.100568
  • 发表时间:
    2024-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Craig Jones;Ashwin Sachdeva;Laura Murphy;Macey Murray;Louise Brown;Eugene McCloskey;Gerhardt Atard;Mahesh Parmar;Nicholas James;Mathew Sydes;Noel Clarke;Janet Brown
  • 通讯作者:
    Janet Brown
A framework for the design and analysis of phase III randomised trials in uncommon diseases
  • DOI:
    10.1186/1745-6215-16-s2-o56
  • 发表时间:
    2015-11-16
  • 期刊:
  • 影响因子:
    2.000
  • 作者:
    Mahesh Parmar;Tim Morris;Matthew Sydes
  • 通讯作者:
    Matthew Sydes
Considerations for using potential surrogate endpoints in cancer screening trials
在癌症筛查试验中使用潜在替代终点的考虑因素
  • DOI:
    10.1016/s1470-2045(24)00015-9
  • 发表时间:
    2024-05-01
  • 期刊:
  • 影响因子:
    35.900
  • 作者:
    Alexis B Webb;Christine D Berg;Philip E Castle;David Crosby;Ruth Etzioni;Larry G Kessler;Usha Menon;Mahesh Parmar;Robert J C Steele;Peter D Sasieni
  • 通讯作者:
    Peter D Sasieni
Non-Newtonian Fluid Speed Breaker
非牛顿流体减速器
Insights from UKCTOCS for design, conduct and analyses of large randomised controlled trials.
UKCTOCS 对大型随机对照试验的设计、实施和分析的见解。
  • DOI:
    10.3310/cldc7214
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    3.6
  • 作者:
    Usha Menon;A. Gentry;M. Burnell;S. Apostolidou;Andy Ryan;Jatinderpal K Kalsi;Naveena Singh;Lesley Fallowfield;Alistair J McGuire;S. Campbell;S. Skates;A. Dawnay;Mahesh Parmar;Ian J Jacobs
  • 通讯作者:
    Ian J Jacobs

Mahesh Parmar的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Mahesh Parmar', 18)}}的其他基金

Evaluating new healthcare technologies in cancer
评估癌症领域的新医疗保健技术
  • 批准号:
    MC_UU_00004/01
  • 财政年份:
    2021
  • 资助金额:
    $ 566.51万
  • 项目类别:
    Intramural
Renewal of the Network of Hubs for Trials Methodology Research.
更新试验方法学研究中心网络。
  • 批准号:
    MR/L004933/1
  • 财政年份:
    2014
  • 资助金额:
    $ 566.51万
  • 项目类别:
    Research Grant
MRC Clinical Trials Unit as the London Hub for Trials Methodology Research
MRC 临床试验单位作为伦敦试验方法学研究中心
  • 批准号:
    MC_EX_G0800814
  • 财政年份:
    2008
  • 资助金额:
    $ 566.51万
  • 项目类别:
    Research Grant
Prison-based Naloxone-on-release RCT to reduce drugs-related deaths
基于监狱的纳洛酮释放随机对照试验可减少与毒品相关的死亡
  • 批准号:
    MC_EX_G0800012
  • 财政年份:
    2008
  • 资助金额:
    $ 566.51万
  • 项目类别:
    Research Grant
A randomised study of interferon (IFN)-alpha, interleukin-2 (IL2) and 5-fluorouracil(FU) vs IFN-alpha alone in advanced
干扰素 (IFN)-α、白介素-2 (IL2) 和 5-氟尿嘧啶 (FU) 与单独使用 IFN-α 的晚期随机研究
  • 批准号:
    E164/52/1
  • 财政年份:
    2006
  • 资助金额:
    $ 566.51万
  • 项目类别:
    Research Grant

相似海外基金

Modernization of an existing X-band EPR spectrometer
现有 X 波段 EPR 光谱仪的现代化改造
  • 批准号:
    534394762
  • 财政年份:
    2024
  • 资助金额:
    $ 566.51万
  • 项目类别:
    Major Research Instrumentation
The Social and Solidarity Economy Movement: Existing and Potential Linkages to Social Work
社会与团结经济运动:与社会工作的现有和潜在联系
  • 批准号:
    24K05468
  • 财政年份:
    2024
  • 资助金额:
    $ 566.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
CRII: SHF: Embedding techniques for mechanized reasoning about existing programs
CRII:SHF:现有程序机械化推理的嵌入技术
  • 批准号:
    2348490
  • 财政年份:
    2024
  • 资助金额:
    $ 566.51万
  • 项目类别:
    Standard Grant
Extending Lifetime of Existing RC Structures Using Cementless FRG: Clarification of Mechanical Performance of FRG-RC Composite Members
使用无水泥 FRG 延长现有 RC 结构的使用寿命:澄清 FRG-RC 复合构件的机械性能
  • 批准号:
    23H00200
  • 财政年份:
    2023
  • 资助金额:
    $ 566.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
Leveraging an Existing Longitudinal Observational Cohort to Understand the Impacts of Cannabis Legalization and the COVID-19 Pandemic on Alcohol and Cannabis Use in At-risk Young Adults
利用现有的纵向观察队列来了解大麻合法化和 COVID-19 大流行对高危年轻人酒精和大麻使用的影响
  • 批准号:
    478397
  • 财政年份:
    2023
  • 资助金额:
    $ 566.51万
  • 项目类别:
    Operating Grants
Development of a mapping chart between existing domestic data and the International Classification of Health Interventions (ICHI)
制定现有国内数据与国际健康干预分类(ICHI)之间的映射图
  • 批准号:
    23K16250
  • 财政年份:
    2023
  • 资助金额:
    $ 566.51万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
All for data, data for all: Improving accessibility of healthcare data through a co-designed augmentation of an existing online rehabilitation application.
一切为了数据,数据为所有人:通过共同设计的现有在线康复应用程序的增强功能,提高医疗保健数据的可访问性。
  • 批准号:
    10054277
  • 财政年份:
    2023
  • 资助金额:
    $ 566.51万
  • 项目类别:
    Grant for R&D
An innovative EdTech platform using AI-powered algorithms to create PSHE-compliant lessons 80% faster than existing methods available to teachers
An%20innovative%20EdTech%20platform%20using%20AI-powered%20algorithms%20to%20create%20PSHE-company%20lessons%2080%%20faster%20than%20existing%20methods%20available%20to%20teachers
  • 批准号:
    10084883
  • 财政年份:
    2023
  • 资助金额:
    $ 566.51万
  • 项目类别:
    Collaborative R&D
Functional Analysis of Distinct and Co-existing Transcriptional Programs Regulating Tumor Dormancy
调节肿瘤休眠的不同和共存转录程序的功能分析
  • 批准号:
    10584353
  • 财政年份:
    2023
  • 资助金额:
    $ 566.51万
  • 项目类别:
Computational Strategies to Tailor Existing Interventions for First Major Depressive Episodes to Inform and Test Personalized Interventions
针对首次严重抑郁发作定制现有干预措施的计算策略,以告知和测试个性化干预措施
  • 批准号:
    10650695
  • 财政年份:
    2023
  • 资助金额:
    $ 566.51万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了